PRL and carcinoma: CAPTEM treatment followed by TMZ monotherapy (TMZ resistant cases) has been reported in eight cases (three ACTH secreting carcinomas, two PRL secreting carcinomas, one null-cell carcinoma, and two cases not stated) (8, 10–12, 42).